952 related articles for article (PubMed ID: 29622697)
1. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
3. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
4. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
6. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
7. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].
Zhou LL; Ye SG; Li P; Tang XC; Liang AB
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526
[No Abstract] [Full Text] [Related]
8. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
[TBL] [Abstract][Full Text] [Related]
9. Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
Pu Y; Zhao Y; Qi Y; Liu Y; Zhang M; Xiao X; Lyu H; Meng J; Zhu H; Xu K; Han W; Zhao M
Int Immunopharmacol; 2024 Mar; 130():111761. PubMed ID: 38422769
[TBL] [Abstract][Full Text] [Related]
10. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
Kadauke S; Myers RM; Li Y; Aplenc R; Baniewicz D; Barrett DM; Barz Leahy A; Callahan C; Dolan JG; Fitzgerald JC; Gladney W; Lacey SF; Liu H; Maude SL; McGuire R; Motley LS; Teachey DT; Wertheim GB; Wray L; DiNofia AM; Grupp SA
J Clin Oncol; 2021 Mar; 39(8):920-930. PubMed ID: 33417474
[TBL] [Abstract][Full Text] [Related]
11. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
[TBL] [Abstract][Full Text] [Related]
12. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Ureshino H; Ando T; Kizuka H; Kusaba K; Sano H; Nishioka A; Itamura H; Shindo T; Kubota Y; Kojima K; Kimura S
Hematol Oncol; 2018 Feb; 36(1):324-327. PubMed ID: 28971493
[TBL] [Abstract][Full Text] [Related]
16. Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia.
Zhang Y; Zhou F; Wu Z; Li Y; Li C; Du M; Luo W; Kou H; Lu C; Mei H
Front Immunol; 2022; 13():914959. PubMed ID: 35799791
[TBL] [Abstract][Full Text] [Related]
17. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
19. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
[TBL] [Abstract][Full Text] [Related]
20. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Fitzgerald JC; Weiss SL; Maude SL; Barrett DM; Lacey SF; Melenhorst JJ; Shaw P; Berg RA; June CH; Porter DL; Frey NV; Grupp SA; Teachey DT
Crit Care Med; 2017 Feb; 45(2):e124-e131. PubMed ID: 27632680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
